Search
01/12/2021
Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group
Caamano, AG, Vicente, AMGM, Maroto, P, Antolin, AR, Sanz, J, Gonzalez, MAV, Climent, MA. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group. Current Oncology. 2021; 28(6)DOI:10.3390/curroncol28060428. PMID:34940067. IF:3.109(Q3/8D).
01/12/2021
Immunotherapy-induced isolated ACTH deficiency in cancer therapy
Iglesias, P, Peiro, I, Biagetti, B, Paja-Fano, M, Cobo, DA, Gomez, CG, Mateu-Salat, M, Genua, I, Majem, M, Riudavets, M, Gavira, J, Lamas, C, Pombo, AF, Guerrero-Perez, F, Villabona, C, Agricola, JMC, Webb, SM, Diez, JJ. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. ENDOCRINE-RELATED CANCER. 2021; 28(12)DOI:10.1530/ERC-21-0228. PMID:34609950. IF:5.905(Q1/3D).
01/11/2021
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers
Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11)DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4.090(Q2/4D).
01/07/2022
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022)
Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02855-2. PMID:35596046. IF:3.400(Q3/6D).
01/07/2022
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022)
Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02846-3. PMID:35567734. IF:3.400(Q3/6D).
01/04/2022
SEOM clinical guideline emesis (2021)
Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM clinical guideline emesis (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02802-1. PMID:35347571. IF:3.400(Q3/6D).